Laboratory for Therapeutical Innovation, UMR 7200 Université de Strasbourg/CNRS, MEDALIS Drug Discovery Center , F-67400 Illkirch, France.
J Chem Inf Model. 2013 Sep 23;53(9):2322-33. doi: 10.1021/ci400303n. Epub 2013 Aug 26.
Computational target fishing is a chemoinformatic method aimed at determining main and secondary targets of bioactive compounds in order to explain their mechanism of action, anticipate potential side effects, or repurpose existing drugs for novel therapeutic indications. Many existing successes in this area have been based on a use of a single computational method to estimate potentially new target-ligand associations. We herewith present an automated workflow using several methods to optimally browse target-ligand space according to existing knowledge on either ligand and target space under investigation. The protocol uses four ligand-based (SVM classification, SVR affinity prediction, nearest neighbors interpolation, shape similarity) and two structure-based approaches (docking, protein-ligand pharmacophore match) in series, according to well-defined ligand and target property checks. The workflow was remarkably accurate (72%) in identifying the main target of 189 clinical candidates and proposed two novel off-targets which could be experimentally validated. Rolofylline, an adenosine A1 receptor antagonist, was confirmed to inhibit phosphodiesterase 5 with a moderate affinity (IC50 = 13.8 μM). More interestingly, we describe a strong binding (IC50 = 142 nM) of a claimed selective phosphodiesterase 10 A inhibitor (PF-2545920) with the cysteinyl leukotriene type 1 G protein-coupled receptor.
计算靶标钓取是一种计算化学方法,旨在确定生物活性化合物的主要和次要靶标,以解释其作用机制、预测潜在的副作用,或重新利用现有药物用于新的治疗适应症。该领域的许多现有成功案例都是基于使用单一计算方法来估计潜在的新靶标-配体关联。在此,我们根据对研究中的配体和靶标空间的现有知识,使用几种方法来自动优化靶标-配体空间的浏览。该方案根据明确的配体和靶标特性检查,依次使用四种基于配体的方法(SVM 分类、SVR 亲和力预测、最近邻插值、形状相似性)和两种基于结构的方法(对接、蛋白-配体药效团匹配)。该工作流程在识别 189 种临床候选药物的主要靶标方面非常准确(72%),并提出了两个可通过实验验证的新潜在靶标。腺苷 A1 受体拮抗剂罗洛非林被证实以中等亲和力(IC50 = 13.8 μM)抑制磷酸二酯酶 5。更有趣的是,我们描述了一种声称的选择性磷酸二酯酶 10A 抑制剂(PF-2545920)与半胱氨酰白三烯 1 G 蛋白偶联受体的强烈结合(IC50 = 142 nM)。